Sol Gel Technologies Ltd
NASDAQ:SLGL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sol Gel Technologies Ltd
Operating Expenses
Sol Gel Technologies Ltd
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Operating Expenses
-$26.9m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Operating Expenses
-$5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Operating Expenses
-$33m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Operating Expenses
-$28.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-4%
|
|
|
S
|
Seach Medical Group Ltd
TASE:SEMG
|
Operating Expenses
-₪37.4m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Operating Expenses
-₪76.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
0%
|
|
Sol Gel Technologies Ltd
Glance View
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
See Also
What is Sol Gel Technologies Ltd's Operating Expenses?
Operating Expenses
-26.9m
USD
Based on the financial report for Dec 31, 2025, Sol Gel Technologies Ltd's Operating Expenses amounts to -26.9m USD.
What is Sol Gel Technologies Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
7%
Over the last year, the Operating Expenses growth was -14%. The average annual Operating Expenses growth rates for Sol Gel Technologies Ltd have been -10% over the past three years , 7% over the past five years .
